Associated Papers
Myeloid neoplasms risks for germline DDX41 pathogenic variants carriers.
Villy MC et al.
European Journal of Human Genetics : Ejhg, 2025
Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndrome.
Kusne Y et al.
British Journal of Haematology, 2025
Prevalence and clinical outcomes of germline variants among patients with myeloid neoplasms.
Kongkiatkamon S et al.
Journal of Clinical Pathology, 2025
The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing.
Maierhofer A et al.
Blood Advances, 2023
37874914 (PubMed )
Supplement: BLOODA_ADV-2023-011389-mmc1.xlsx › Table_S3
Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms.
Badar T et al.
Haematologica, 2023
Current Understanding of DDX41 Mutations in Myeloid Neoplasms.
Kim K et al.
Cancers, 2023
Clinical and mechanistic insights into the roles of DDX41 in haematological malignancies.
Weinreb JT et al.
Febs Letters, 2022
Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations.
Qu S et al.
British Journal of Haematology, 2021
Clinical features of DDX41 mutation-related diseases: a systematic review with individual patient data.
Wan Z et al.
Therapeutic Advances in Hematology, 2021
34349893 (PubMed )
Supplement: sj-xlsx-3-tah-10.1177_20406207211032433.xlsx › Table_S2
Novel DDX41 variants in Thai patients with myeloid neoplasms.
Polprasert C et al.
International Journal of Hematology, 2020
Select a paper to view details